As mentioned above, catumaxomab, which targets EpCAM andCD3, was approved for the intraperitoneal use in ovarian cancer patients and others with malignant ascites and EpCAM+ tumours in Europe in 2009 [278,279]. Here, EPCAM is linked to ovarian carcinoma.